Intraperitoneal nivolumab in a patient with pancreatic cancer and refractory malignant ascites
Author:
Funder
Ministry of Science and Technology, Taiwan
National Health Research Institutes
Ministry of Health and Welfare
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference10 articles.
1. Malignant ascites: systematic review and guideline for treatment;Becker;Eur J Canc,2006
2. Omental milky spots develop in the absence of lymphoid tissue-inducer cells and support B and T cell responses to peritoneal antigens;Rangel-Moreno;Immunity,2009
3. Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites;Takahara;Invest New Drugs,2016
4. LBA65 The Canadian Cancer Trials Group PA.7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)
5. Cellular composition of milky spots in the human greater omentum: an immunochemical and ultrastructural study;Krist;Anat Rec,1995
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Evaluating Treatment Patterns and the Role of Neoadjuvant Chemotherapy in Plasmacytoid Urothelial Carcinoma: Insights from a Combined National and Institutional Series;Cancers;2024-09-01
2. Phase I/II Clinical Study of PRaG Regimen Combined With Intraperitoneal Infusion of PD-1 Inhibitor for Advanced Refractory Solid Tumors With Cancerous Ascites (PRaG4.0P Study);Technology in Cancer Research & Treatment;2024-01
3. Malignant ascites: Current therapy options and treatment prospects;Cancer Treatment Reviews;2023-12
4. Malignant ascites in pancreatic cancer: Pathophysiology, diagnosis, molecular characterization, and therapeutic strategies;Frontiers in Oncology;2023-03-16
5. Gemcitabine/paclitaxel;Reactions Weekly;2021-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3